GTC Biotherapeutics (fka GTCB)

[quantumdot]

>5. If Leo’s phase-2 data in DIC are compelling, Ovation may decide to pursue both CABG/HR and DIC. However, if Ovation opts out of pursuing DIC, GTC will be free to partner the DIC indication with another company.<

Dew, do Ovation effectively have first right of refusal on all ATryn applications in US now? If so it seems like a very cheap call option.